Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710

Benzinga Newsdesk www.benzinga.com Negative 86.7%

Neg 86.7% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.